ArticleThe American journal of case reports2025
Treatment of Multiple Recalcitrant Warts in an Immunocompromised Patient Using Purified Protein Derivative (PPD) Injection: A Case Report.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Warts are common cutaneous viral infections primarily caused by human papillomavirus (HPV). They occur in all age groups, with immunocompromised individuals being particularly susceptible. Patients with compromised immune systems, such as those with acquired immunodeficiency syndrome (AIDS), organ transplant recipients, and individuals on immunosuppressive therapies, are at a higher risk of developing warts. These patients are also more likely to have severe and persistent warts, often necessitating multiple treatment approaches. Conventional therapies such as cryotherapy, laser ablation, and topical treatments often yield suboptimal results in this population due to their compromised immune response. Although intralesional immunotherapy, such as purified protein derivative (PPD), has been shown to stimulate a systemic immune response and facilitate wart clearance, its use in immunosuppressed individuals remains under-reported and under-utilized in clinical practice. CASE REPORT We report the case of a 70-year-old woman with a history of immunosuppression who presented with multiple recalcitrant warts on her left hand. Due to the persistence of lesions despite previous treatments, she received PPD injection sessions in a single lesion. Remarkably, all of her warts regressed completely within 6 weeks, with no recurrence observed during follow-up. No adverse effects were reported, highlighting the safety of this approach. CONCLUSIONS This case underscores the potential of PPD immunotherapy as an effective, safe, and well-tolerated treatment modality for warts in immunocompromised patients. Given its immunostimulatory properties and ability to induce systemic clearance, PPD should be considered a valuable alternative for managing refractory warts in this high-risk population. Further studies are warranted to establish standardized protocols and optimize its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.